The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
Open accessAbstract
SummaryObjectives Gallbladder and cholangiocarcinomas represent a heterogeneous group of malignant diseases that commonly present at an advanced stage and have limited therapeutic options. Based on the role of the Ras-Raf-Mek-Erk pathway and the VEGF axis in biliary carcinomas, we conducted a phase II study of sorafenib in patients with advanced biliary cancers. Methods Eligible patients had no prior therapy for metastatic or unresectable disease. Sorafenib was administered at 400 mg po twice daily continuously. Results The study was terminated after the first stage of accrual due to failure to meet the primary objective. A confirmed response rate of 0% (0%–11%) was observed. Thirty-nine percent of patients demonstrated stable disease (including 2 with unconfirmed PR). PFS was 3 months (95% CI: 2–4 months) and OS 9 months (95% CI: 4–12 months). The most common grade 3 and 4 toxicities included hand-foot skin reaction (13%), bilirubin elevation (13%), venous thromboembolism (10%), AST/ALT elevation (10%) and elevated alkaline phosphatase (10%). Conclusion While treatment with sorafenib did not result in objective responses, patients with biliary cancers receiving this drug had some therapeutic benefit. Additional studies with sorafenib in combination with chemotherapy or other targeted agents may be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cited by
Gallbladder Cancer in the 21st Century
Kanthan, R., Senger, J.-L., Ahmed, S., & Kanthan, S. C. (2015) · Journal of Oncology · doi:10.1155/2015/967472 · Cited by 295
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187
Metadata
- Authors
- El-Khoueiry, A. B., Rankin, C. J., Ben-Josef, E., Lenz, H.-J., Gold, P. J., Hamilton, R. D., Govindarajan, R., Eng, C., & Blanke, C. D.
- Venue
- Investigational New Drugs
- Published
- 2011-07-12
- Volume
- 30
- Issue
- 4
- Pages
- 1646-1651
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2063432158
- Cited by
- 160
- References
- 1
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. https://app.cochat.ai/papers/10.1007/s10637-011-9719-0
- The paper
- El-Khoueiry, A. B., Rankin, C. J., Ben-Josef, E., Lenz, H.-J., Gold, P. J., Hamilton, R. D., Govindarajan, R., Eng, C., & Blanke, C. D. (2012). SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Investigational New Drugs. https://doi.org/10.1007/s10637-011-9719-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.